Table 1.

Patient demographics at baseline

	ICB+, n = 30	ICB−, n = 111	p
Sex, male (%)	14 (46.7)	37 (33.3)	0.178
Age, median (IQR)	68 (63.3–75.8)	71 (64.5–75)	0.542
Onset age, year, median (IQR)	62 (53.5–68.8)	65 (59–70)	0.25
Disease duration, year, median (IQR)	6.5 (10–26)	5 (3–9)	0.091
Olfactory dysfunction, n (%)	17 (56.7)	40 (36)	0.041
Dyskinesia, n (%)	8 (26.7)	23 (20.7)	0.485
Deep brain stimulation treatment, n (%)	0 (0)	3 (2.7)	0.363
MMSE score, median (IQR)	28 (25–29)	27 (25–29.5)	0.897
HY stage, median (IQR)	2.5 (2–3)	2 (2–3)	0.313
UPDRS part III, median (IQR)	14 (10–26)	19 (12–28.5)	0.174
Medication
L‐DOPA use, n (%)	28 (93.3)	106 (95.5)	0.629
L‐DOPA use, monotherapy, n (%)	8 (26.7)	31 (27.9)	0.891
DA use, n (%)	20 (66.7)	46 (41.4)	0.014
Pramipexole IR use, n (%)	4 (13.3)	5 (4.5)	0.079
Pramipexole ER use, n (%)	4 (13.3)	19 (17.1)	0.619
Ropinirole CR use, n (%)	3 (10)	17 (15.3)	0.459
Rotigotine use, n (%)	0 (0)	7 (6.3)	0.158
Pergolide use, n (%)	7 (23)	6 (5.4)	0.003
Amantadine use, n (%)	12 (40)	23 (20.7)	0.033
Selegiline use, n (%)	6 (20)	16 (14.4)	0.454
Entacapone use, n (%)	5 (16.7)	13 (11.7)	0.471
Zonisamide use, n (%)	9 (30)	19 (17.1)	0.117
Istradefylline use, n (%)	1 (3.3)	6 (5.4)	0.643
LED‐total mg, median (IQR)	657 (450–845)	530 (378–782)	0.182
LED‐L‐DOPA mg, median (IQR)	450 (300–600)	400 (300–525)	0.329
LED‐DA mg, median (IQR)	125 (0–197)	38 (0–240)	0.815
LED‐other PD drugs mg, median (IQR)	12.5 (0–150)	0 (0–100)	0.110

CR: controlled release; DA: dopamine agonist; ER: extended release; HY: Hoehn and Yahr scale; ICB: impulse control behavior; IQR: interquartile range; IR: immediate release; LED: L‐DOPA equivalent dose; MMSE: Mini–Mental State Examination; UPDRS: United Parkinson's Disease Rating Scale.

Bold indicates p <0.01.